Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland.
Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
Cytotherapy. 2024 Sep;26(9):1084-1094. doi: 10.1016/j.jcyt.2024.04.002. Epub 2024 Apr 7.
BACKGROUND AIMS: Chimeric antigen receptor (CAR) T-cell products are commonly generated using lentiviral vector (LV) transduction. Optimal final formulation buffer (FFB) supporting LV stability during cryostorage is crucial for cost-effective manufacturing. METHODS: To identify the ideal LV FFB composition for ex vivo CAR-T production, primary human T cells were transduced with vesicular stomatitis virus G-protein (VSV-G) -pseudotyped LVs (encoding a reporter gene or an anti-CD19-CAR). The formulations included phosphate-buffered saline (PBS), HEPES, or X-VIVO 15, and stabilizing excipients. The functional and viral particle titers and vector copy number were measured after LV cryopreservation and up to 24 h post-thaw incubation. CAR-Ts were produced with LVs in selected FFBs, and the resulting cells were characterized. RESULTS: Post-cryopreservation, HEPES-based FFBs provided higher LV functional titers than PBS and X-VIVO 15, and 10% trehalose-20 mM MgCl improved LV transduction efficiency in PBS and 50 mM HEPES. Thawed vectors remained stable at +4°C, while a ≤ 25% median decrease in the functional titer occurred during 24 h at room temperature. Tested excipients did not enhance LV post-thaw stability. CAR-Ts produced using LVs cryopreserved in 10% trehalose- or sucrose-20 mM MgCl in 50 mM HEPES showed comparable transduction rates, cell yield, viability, phenotype, and in vitro functionality. CONCLUSION: A buffer consisting of 10% trehalose-20 mM MgCl in 50 mM HEPES provided a feasible FFB to cryopreserve a VSV-G -pseudotyped LV for CAR-T-cell production. The LVs remained relatively stable for at least 24 h post-thaw, even at ambient temperatures. This study provides insights into process development, showing LV formulation data generated using the relevant target cell type for CAR-T-cell manufacturing.
背景目的:嵌合抗原受体(CAR)T 细胞产品通常通过慢病毒载体(LV)转导生成。在冷冻储存过程中支持 LV 稳定性的最佳最终制剂缓冲液(FFB)对于具有成本效益的制造至关重要。
方法:为了确定用于体外 CAR-T 生产的理想 LV FFB 组成,使用水疱性口炎病毒 G 蛋白(VSV-G)-假型 LV(编码报告基因或抗 CD19-CAR)转导原代人 T 细胞。制剂包括磷酸盐缓冲盐水(PBS)、HEPES 或 X-VIVO 15,以及稳定赋形剂。在 LV 冷冻保存后以及解冻后 24 小时内测量功能性和病毒颗粒滴度和载体拷贝数。使用选定 FFB 中的 LV 生产 CAR-T,并对产生的细胞进行表征。
结果:冷冻保存后,基于 HEPES 的 FFB 提供的 LV 功能滴度高于 PBS 和 X-VIVO 15,并且 10%海藻糖-20 mM MgCl 提高了 PBS 和 50 mM HEPES 中的 LV 转导效率。解冻后的载体在+4°C 下保持稳定,而在室温下 24 小时内功能性滴度中位数下降≤25%。测试的赋形剂不会增强 LV 解冻后的稳定性。使用冷冻保存在 10%海藻糖或 20 mM MgCl 蔗糖中的 LV 生产的 CAR-T 显示出可比的转导率、细胞产量、活力、表型和体外功能。
结论:由 10%海藻糖-20 mM MgCl 在 50 mM HEPES 组成的缓冲液为生产 CAR-T 细胞提供了一种可行的 FFB 来冷冻保存 VSV-G-假型 LV。解冻后至少 24 小时,LV 仍保持相对稳定,即使在环境温度下也是如此。这项研究为工艺开发提供了一些见解,显示了使用与 CAR-T 细胞制造相关的靶细胞类型生成的 LV 配方数据。
J Immunother Cancer. 2017-5-16